SCHEDULE: BlackRock Discloses 6.4% Stake in InfuSystem Holdings

BlackRock, Inc. has reported beneficial ownership of 6.4% of InfuSystem Holdings, Inc. common stock as of June 30, 2026.

Summary

• BlackRock, Inc. has filed a Schedule 13G, indicating it beneficially owns 1,286,129 shares of InfuSystem Holdings, Inc. common stock.
• This ownership represents 6.4% of the class of securities.
• The filing specifies BlackRock's sole voting power is 1,269,273 shares and sole dispositive power is 1,286,129 shares.
• The reporting is done by BlackRock, Inc. and its subsidiaries and affiliates, with specific business units identified.
• The filing confirms that no single person's interest in InfuSystem Holdings, Inc. exceeds five percent of the total outstanding common shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a routine disclosure of institutional ownership without specific performance data or strategic announcements that would typically sway sentiment.

Positives

• BlackRock, a significant institutional investor, has disclosed a substantial ownership stake, which can be viewed as a positive signal of confidence in the company.
• The filing indicates clear and sole dispositive and voting power for BlackRock, suggesting straightforward control over their investment.

Negatives

• The filing does not contain any negative financial results or operational issues.
• No specific negative commentary or forward-looking concerns are present in this disclosure.

Risks

• The filing does not explicitly mention any current issues or potential future challenges for InfuSystem Holdings, Inc.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding InfuSystem Holdings, Inc.'s future performance.

Management Comments

• BlackRock, Inc. certifies that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that institutional ownership filings like this Schedule 13G are common for publicly traded companies and provide transparency on significant shareholder positions. BlackRock's involvement suggests potential institutional interest in the healthcare technology sector where InfuSystem operates.

Comparison to Industry Standards

• As a Schedule 13G filing, this is a standard disclosure for significant institutional investors. BlackRock is a major global asset manager, and its holdings are typically monitored by the market.
• The 6.4% stake is a notable but not controlling interest, common for institutional investors who may hold positions across various companies in the healthcare sector.

Stakeholder Impact

• Shareholders: The increased visibility of a large institutional holder like BlackRock may attract further investor interest.
• Management: The company's management will be aware of BlackRock's significant stake and voting power.
• Creditors: No direct impact mentioned, but stable institutional ownership can be seen as a positive for company stability.

Next Steps

• BlackRock will continue to hold or manage its investment in InfuSystem Holdings, Inc. according to its investment strategies.
• The company's management will continue to operate the business, with BlackRock as a significant shareholder.

Key Dates

Keywords

InfuSystem Holdings, BlackRock, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Ownership Stake